Document is current
Any future updates will be listed below
-
Authors
He, Yonghan
Koch, Raphael
Budamagunta, Vivekananda
Zhang, Peiyi
Zhang, Xuan
Khan, Sajid
Thummuri, Dinesh
Ortiz, Yuma T.
Zhang, Xin
Lv, Dongwen
Wiegand, Janet S.
Li, Wen
Palmer, Adam C.
Zheng, Guangrong
Weinstock, David M.
Zhou, Daohong http://orcid.org/0000-0002-2400-6461
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01CA211963, R01CA219836, R01CA242003, R21CA223371, R35CA239158, R01CA241191)
Deutsche Forschungsgemeinschaft (KO 4627/2-1)
Leukemia and Lymphoma Society (#7011-16)
- License Information
-
More Information
Article History
Received: 7 May 2020
Accepted: 29 June 2020
First Online: 16 July 2020
Ethics approval and consent to participate
: Animal experiments were approved by the Animal Care and Use Committee of University of Florida. There is no human subject participation.
: This study does not include any individual person’s data in any form.
: Y.H., S.K., X. Z, G.Z., and D.Z. are inventors of two pending patent applications for use of Bcl-xL PROTACs as senolytic and antitumor agents. G.Z. and D.Z. are co-founders of and have equity in Dialectic Therapeutics, which develops Bcl-xL PROTACs to treat cancer. D.M.W. received research support from AbbVie, Aileron, Daiichi Sankyo, Surface Oncology, and AstraZeneca and licensing fees from AstraZeneca and Aileron and is a paid consultant for AstraZeneca, EDO Biosciences, Myeloid Therapeutics, Bantam Therapeutics, and Travera. The remaining authors declare no competing financial interests.
